493 related articles for article (PubMed ID: 11248160)
1. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
5. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
Schackman BR; Freedberg KA; Weinstein MC; Sax PE; Losina E; Zhang H; Goldie SJ
Arch Intern Med; 2002 Nov; 162(21):2478-86. PubMed ID: 12437408
[TBL] [Abstract][Full Text] [Related]
7. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
Johri M; David Paltiel A; Goldie SJ; Freedberg KA
Med Care; 2002 May; 40(5):429-41. PubMed ID: 11961477
[TBL] [Abstract][Full Text] [Related]
8. The lifetime cost of current human immunodeficiency virus care in the United States.
Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
[TBL] [Abstract][Full Text] [Related]
9. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
10. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
11. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
15. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.
Schackman BR; Goldie SJ; Weinstein MC; Losina E; Zhang H; Freedberg KA
Am J Public Health; 2001 Sep; 91(9):1456-63. PubMed ID: 11527782
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
Hornberger J; Kilby JM; Wintfeld N; Green J
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
20. Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.
Ward T; Sugrue D; Hayward O; McEwan P; Anderson SJ; Lopes S; Punekar Y; Oglesby A
J Manag Care Spec Pharm; 2020 Feb; 26(2):104-116. PubMed ID: 32011956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]